HC Wainwright Analysts Lift Earnings Estimates for uniQure

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for uniQure from ($0.73) to ($0.66), while maintaining a "Buy" rating and a price target of $110.00 on the stock.
• Analysts from various firms have significantly increased their price targets for uniQure, with Guggenheim raising theirs from $28.00 to $95.00.
• uniQure's shares recently increased by 9.5%, reflecting a market capitalization of $3.18 billion and a P/E ratio of -14.78.

uniQure N.V. (NASDAQ:QURE - Free Report) - HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for shares of uniQure in a report released on Monday, October 6th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($0.66) per share for the quarter, up from their prior forecast of ($0.73). HC Wainwright has a "Buy" rating and a $110.00 price target on the stock. The consensus estimate for uniQure's current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure's Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.88) EPS, Q1 2026 earnings at ($0.59) EPS, Q2 2026 earnings at ($0.68) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at $0.00 EPS, FY2026 earnings at ($1.73) EPS, FY2027 earnings at $6.96 EPS and FY2028 earnings at $13.85 EPS.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The company had revenue of $5.26 million during the quarter, compared to analysts' expectations of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.

Several other equities research analysts have also recently weighed in on QURE. Guggenheim upped their target price on uniQure from $28.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. Leerink Partners upped their price objective on uniQure from $48.00 to $68.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 24th. Weiss Ratings reiterated a "sell (d-)" rating on shares of uniQure in a report on Saturday, September 27th. Stifel Nicolaus boosted their price target on uniQure from $30.00 to $65.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. Finally, Chardan Capital lifted their price objective on shares of uniQure from $35.00 to $76.00 and gave the stock a "buy" rating in a research note on Thursday, September 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $71.75.

uniQure Stock Up 9.5%

Shares of QURE opened at $57.92 on Wednesday. The firm has a market capitalization of $3.18 billion, a P/E ratio of -14.78 and a beta of 0.56. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a 12-month low of $5.23 and a 12-month high of $60.70. The firm has a fifty day moving average price of $23.23 and a 200-day moving average price of $16.96.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP grew its stake in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after acquiring an additional 1,767,572 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in uniQure by 3.8% in the first quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock valued at $29,213,000 after acquiring an additional 101,598 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of uniQure by 24.2% in the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company's stock valued at $38,345,000 after purchasing an additional 535,163 shares during the last quarter. Jefferies Financial Group Inc. acquired a new position in uniQure in the second quarter valued at about $29,217,000. Finally, JPMorgan Chase & Co. increased its position in shares of uniQure by 471.7% during the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock valued at $25,199,000 after acquiring an additional 1,491,486 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

Insider Buying and Selling

In other news, CEO Matthew C. Kapusta sold 226,316 shares of the business's stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the sale, the chief executive officer owned 651,454 shares of the company's stock, valued at $27,009,282.84. The trade was a 25.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Christian Klemt sold 15,000 shares of the firm's stock in a transaction dated Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the transaction, the chief financial officer directly owned 217,730 shares in the company, valued at $11,975,150. This represents a 6.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 244,316 shares of company stock worth $10,328,181 in the last quarter. 4.79% of the stock is currently owned by company insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.